Edition:
India

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

3.69USD
12:40am IST
Change (% chg)

$0.10 (+2.92%)
Prev Close
$3.59
Open
$3.56
Day's High
$3.73
Day's Low
$3.55
Volume
170,743
Avg. Vol
224,260
52-wk High
$5.08
52-wk Low
$2.53

Latest Key Developments (Source: Significant Developments)

Affimed Announces Positive Clinical Data On AFM13 In CD30+ Lymphoma
Monday, 24 Jun 2019 

June 24 (Reuters) - AFFIMED NV ::ANNOUNCES CLINICAL DATA UPDATE ON LEAD PRODUCT CANDIDATE AFM13 IN CD30+ LYMPHOMA AT ICML 2019.COMBINATION OF AFM13 AND PEMBROLIZUMAB WAS WELL TOLERATED.DATA SUPPORT POTENTIAL OF AFM13 AS A NOVEL IMMUNO-THERAPEUTIC TO TREAT CD30-EXPRESSING LYMPHOMAS.REGISTRATION-DIRECTED PHASE 2 INTERNATIONAL MULTICENTER STUDY OF AFM13 IN REFRACTORY PERIPHERAL T CELL LYMPHOMA (PTCL) AND T-MF IS PLANNED.AFM13 WAS WELL TOLERATED AND RESULTED IN A HIGH ORR OF 50% (1 CR AND 4 PRS) INCLUDING THERAPEUTIC ACTIVITY POST-BV FAILURE.ANALYSIS OF TUMOR BIOPSIES SHOWED INCREASED NUMBERS OF NK CELLS BOTH BEFORE AND DURING TREATMENT WITH AFM13 AMONGST THE PATIENTS RESPONDING TO THERAPY.COMBINATION OF AFM13 AND PEMBROLIZUMAB ACHIEVED HIGH AND DEEP RESPONSE RATES EVEN IN PATIENTS WHO WERE REFRACTORY TO BRENTUXIMAB VEDOTIN.  Full Article

Affimed Announces Research And Development Strategy To Focus On Innate Immunity Portfolio Reports First Quarter 2019 Financial Results And Operational Progress
Wednesday, 22 May 2019 

May 22 (Reuters) - Affimed NV ::AFFIMED ANNOUNCES RESEARCH AND DEVELOPMENT STRATEGY TO FOCUS ON INNATE IMMUNITY PORTFOLIO; REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q1 EARNINGS PER SHARE EUR 0.03.Q1 REVENUE EUR 11.4 MILLION VERSUS EUR 500,000.CO TO FOCUS ON DEVELOPMENT OF AFM13, AFM24 AND PRECLINICAL INNATE CELL ENGAGERS, DECIDES TO TERMINATE AFM11 T CELL ENGAGER PHASE 1 PROGRAM.SEES CASH, CASH EQUIVALENTS,SHORT-TERM DEPOSITS AS OF MARCH 31, 2019 TO ENABLE CO TO FUND PLANNED CLINICAL DEVELOPMENT,EARLY DEVELOPMENT ACTIVITIES INTO 2021.  Full Article

Affimed Reports 2018 Financial Results
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Affimed NV ::AFFIMED REPORTS 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.AFFIMED NV - AFM24: IND SUBMISSION PLANNED FOR MID-2019; PLANS TO INITIATE FIRST-IN-HUMAN STUDY IN SECOND HALF OF 2019.AFFIMED NV - CLINICAL DATA UPDATES FROM MONOTHERAPY STUDY AND COMBINATION STUDY WITH KEYTRUDA (PEMBROLIZUMAB) EXPECTED IN 2019.  Full Article

Affimed Places Afm11 early-stage study On Clinical Hold
Tuesday, 9 Oct 2018 

Oct 8 (Reuters) - Affimed NV ::AFFIMED PLACES AFM11 (CD19/CD3-TARGETING T CELL ENGAGER) PHASE 1 PROGRAM ON CLINICAL HOLD.AFFIMED NV - ANNOUNCED THAT IT HAS PLACED AFM11 (CD19/CD3-TARGETING T CELL ENGAGER) ON CLINICAL HOLD.AFFIMED NV - CLINICAL HOLD WAS INITIATED AFTER OCCURRENCE OF SERIOUS ADVERSE EVENTS (SAES) IN THREE PATIENTS.AFFIMED NV - SERIOUS ADVERSE EVENTS (SAES) IN 3 PATIENTS, INCLUDED A DEATH IN ALL STUDY AND TWO LIFE-THREATENING EVENTS IN NHL STUDY.AFFIMED NV - SAES OCCURRED IN PATIENTS ENROLLED IN HIGHEST DOSE COHORTS OF EACH STUDY.AFFIMED NV - CLINICAL HOLD DOES NOT AFFECT ONGOING DEVELOPMENT OF CO'S NK CELL ENGAGER PROGRAMS, WHICH ARE BASED ON TARGETING NK CELL RECEPTOR CD16A.  Full Article

Sgr Sagittarius Holding AG Cuts Stake In Affimed NV To 11.9 Pct From 14.3 Pct
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - Affimed NV ::SGR SAGITTARIUS HOLDING AG CUTS STAKE IN AFFIMED NV TO 11.9 PERCENT AS OF SEPTEMBER 10 FROM A STAKE OF 14.3 PERCENT AS OF MARCH 20 - SEC FILING.  Full Article

Affimed Reports Q2 Loss Per Share EUR 0.13
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Affimed NV ::AFFIMED REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2018 AND OPERATIONAL PROGRESS.Q2 LOSS PER SHARE EUR 0.13.Q2 REVENUE EUR 200,000 VERSUS EUR 500,000.Q2 REVENUE VIEW EUR 407,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW EUR -0.15 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS TOTALED EUR 47.4 MILLION AS OF JUNE 30, 2018 COMPARED TO EUR 39.8 MILLION AS OF DECEMBER 31, 2017.  Full Article

Affimed Reports Q4 Loss Per Share EUR 0.14
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Affimed Nv ::AFFIMED REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR END 2017.Q4 LOSS PER SHARE EUR 0.14.Q4 EARNINGS PER SHARE VIEW EUR -0.17 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE EUR 600,000 VERSUS EUR 1.4 MILLION.Q4 REVENUE VIEW EUR 1.8 MILLION -- THOMSON REUTERS I/B/E/S.‍OPERATIONS, INCLUDING CLINICAL DEVELOPMENT AND EARLY DEVELOPMENT ACTIVITIES, ARE EXPECTED TO BE FUNDED AT LEAST UNTIL Q4 OF 2019​.  Full Article

Affimed prices 11.5 mln common shares at $2 per share
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.5 MILLION COMMON SHARES PRICED AT $2.00PER SHARE.  Full Article

Affimed Announces Proposed Public Offering Of Common Stock
Tuesday, 13 Feb 2018 

Feb 12 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Affimed Reports New Data For AFM13 From Two Separate Clinical Trials
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Affimed Nv ::AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS.AFFIMED NV - ‍DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED​.AFFIMED NV - ‍DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS​.AFFIMED NV - ‍EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA​.AFFIMED NV - ‍AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY​.AFFIMED NV - ‍ AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE.  Full Article